tbuckley/cabot-search huggingface dataset:
Analysis of Serial Peripheral Blood Transcriptomes from Peanut Allergic Children Undergoing Double-blind, Placebo-controlled Oral Food Challenges Reveals Key Drivers of the Acute Allergic Response to Peanut
Authors: Corey Watson, Ariella Cohain, Robert Griffin, Noam Beckmann, Alexander Grishin, Halina Haczynska, Peter Dawson, Alice Henning, Gabriel Hoffman, Hardik Shah, Robert A. Wood, A. Wesley Burks, Stacie M. Jones, Donald Y.M. Leung, Scott H. Sicherer, Hugh A. Sampson, Andrew Sharp, Eric Schadt, Supinda Bunyavanich
Journal: Journal of Allergy and Clinical Immunology (2017)
Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,
Authors: Tadeusz Robak, Jerzy Blonski, Krzysztof Jamroziak, Malgorzata Calbecka, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Anna Dmoszynska, Malgorzata Kowal, Janusz Kloczko, Jaroslaw Piszcz, Beata Stella-Holowiecka, Kazimierz Sulek, Kazimierz Kuliczkowski, Stanislaw Potoczek, Krzysztof Warzocha, Ewa Lech-Maranda, Aleksander Skotnicki, Piotrowska Magdalena, Andrzej Moskwa, Krystyna M Zawilska, Joanna Gora-Tybor
Journal: Blood (2011)
Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab
Authors: Y. Nakamura, S. Kitano, A. Takahashi, A. Tsutsumida, K. Namikawa, I. Muto, M. Ueno, Y. Muto, N. Yamazaki
Journal: Annals of Oncology (2016)
A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
Authors: A.B. Apolo, A. Mortazavi, M. Stein, S.K. Pal, N. Davarpanah, H.L. Parnes, Y.M. Ning, D.C. Francis, L.M. Cordes, M. Berniger, S.M. Steinberg, P. Monk, T. Lancaster, T. Mayer, R. Costello, D.P. Bottaro, W.L. Dahut
Journal: Annals of Oncology (2016)
Surgery and chemoradiotherapy in stage II and III esophageal cancer: A retrospective analysis of first-course treatment across different insurances using the NCDB.
Authors: Lauren Brin, Apar Kishor Ganti, Xiang Fang, Mary Warlaumont, Timothy Fuller, Naomi Whittaker, Peter T. Silberstein
Journal: Journal of Clinical Oncology (2012)

29 Background: The current standard of care for stage II/III esophageal carcinoma for patients who can withstand aggressive therapy is chemotherapy, radiotherapy and surgery (tri-modality therapy). This is the largest study of its kind to date. Methods: Using the National Cancer Database (NCDB) 46,758 patients diagnosed with stage II/III esophageal carcinoma between 2000 and 2009 were identified. The NCDB database includes data from 70% of cancer patients in the US. Results: In stage II/III esophageal cancer private insurance holders received more tri-modality therapy (39%) than VA insurance (18%), Medicaid (22%), Medicare (18%), and the uninsured (19%) (p&lt;0.0001). There was no statistically significant difference in the amount of tri-modality therapy received in patients with VA, Medicare, or no insurance. Medicaid patients received more tri-modality therapy than Medicare, uninsured, and VA patients (p&lt;0.05). VA and uninsured patients received no treatment more frequently (13%) than those with private insurance (5%), Medicare (10%), and Medicaid (9%) (p&lt;0.0003). Patients over 70 less frequently underwent tri-modality therapy (13%) as compared to those under 70 (34%, p&lt;0.0001). Conclusions: Although VA, Medicare, and the uninsured patients received similar rates of tri-modality therapy (18-19%), it was much less than private insurance holders (39%). Medicaid patients received less tri-modality therapy than private insurance holders despite similar ages. Uninsured patients received a similar amount of tri-modality therapy as those with VA and Medicare. [Table: see text]
NIMG-23. DEVELOPMENT OF PRACTICE ALGORITHMS TO GUIDE TREATMENT PLANNING WITH TTFIELDS FOR THE MANAGEMENT OF GLIOBLASTOMA
Authors: John Trusheim, Erin Dunbar, James Battiste, Fabio Iwamoto, Nimesh Mohilie, Denise Damek, Daniela Bota, Jennifer Connelly
Journal: Neuro-Oncology (2016)

TTFields are becoming a key modality in the management of glioblastoma, and are delivered to patients in 2 paired orthogonal planes via direct application of transducer arrays to the shaved scalp. Array placement is planned through the NovoTAL software using MRI morphometric head size and tumor location measurements. As TTFields non-uniformly distribute through the brain parenchyma, treatment planning aims to optimize field intensity delivered to the tumor volume. Tumors can be radiographically heterogeneous, presenting with enhancing and/or nonenhancing areas on imaging. Newly diagnosed patients may receive TTFields following a gross total resection with no post-op MRI enhancement and interpreting imaging in recurrent disease may be complicated due to the effects of prior therapies and patterns of recurrence. Therefore clinical guidance is needed for physicians to appropriately plan TTFields across a spectrum of clinical scenarios, and to ensure standardization of practices across specialties and institutions. Neuro-oncologists with significant collective TTFields planning experience (mean 31, range 15-68 cases in 2015) collaboratively developed TTFields treatment planning algorithms, which have been prospectively incorporated into draft practice guidelines developed for the multi-disciplinary team caring for glioblastoma patients. Algorithms were developed for enhancing and non-enhancing tumors in the newly diagnosed and recurrent disease settings, for multi-focal and gross totally resected tumors, and for assessing response to therapy in these diverse clinical settings. Guidance has also been developed for re-planning therapy based on sequential imaging changes. TTFields in combination with TMZ have improved overall survival in newly diagnosed glioblastoma. As TTFields become increasingly incorporated into standard glioblastoma management, clinical practice guidelines are acutely needed in order to optimize efficacy and outcomes via standardization of treatment across patients and institutions. The development of these algorithms represents the first-ever clinical practice guidelines for the use of TTFields in glioblastoma.
177P New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the Japanese Classification of Colorectal Carcinoma: A multi-institutional study.
Authors: S. Noura, M. Ohue, J. Hasegawa, M. Hirota, T. Matsumura, Y. Ito, N. Miyoshi, H. Kobayashi, K. Kotake, K. Sugihara
Journal: Annals of Oncology (2016)
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial
Authors: L. Moscetti, M.A. Fabbri, P. Vici, C. Natoli, T. Gamucci, I. Sperduti, L. Pizzuti, L. Iezzi, E. Iattoni, C.L. Roma, A. Vaccaro, G. D'Auria, M. Mauri, E.M. Ruggeri
Journal: Annals of Oncology (2016)
Analysis of Hypersensitivity Reactions to Betalactam Antibiotics during a 30 Year Period in a Drug Allergy Unit
Authors: Esther Barrionuevo, Inmaculada DoÑa, Arturo Ruiz San Francisco, Maria Dolores Ruiz, Tahia D. Fernandez, Maria I. Montañez, James R. Perkins, Miguel Blanca, Maria J. Torres
Journal: Journal of Allergy and Clinical Immunology (2017)
Further Evidence That HO-1 Regulates SDF-1 Expression in the Bone Marrow Microenvironment and That HO-1-Deficient Mice Show a Defect in the SDF-1–CXCR4 Retention Axis of Hematopoietic Stem/Progenitor Cells in Bone Marrow and Thus Are Easy Mobilizers - Studies in HO-1 Mutant Mice, Irradiation Chimeras, and the Effect of in Vivo Pharmacological Inhibition of HO-1
Authors: Marcin Wysoczynski, Janina Ratajczak, Gregg Rokosh, Roberto Bolli, Mariusz Z Ratajczak
Journal: Blood (2012)
Iron Overload of the Kidneys of Patients with Thalassemia and Sickle-Cell Disease: Final Results of a Prospective Study in 224 Patients Using Magnetic Resonance Imaging T2 and R2* Techniques
Authors: Ersi Voskaridou, Dimitrios Christoulas, Maria Dimopoulou, Konstantina Repa, Maroussa Douskou, Evangelos Terpos
Journal: Blood (2015)
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
Authors: Johan Erlandsson, Torbjörn Holm, David Pettersson, Åke Berglund, Björn Cedermark, Calin Radu, Hemming Johansson, Mikael Machado, Fredrik Hjern, Olof Hallböök, Ingvar Syk, Bengt Glimelius, Anna Martling
Journal: The Lancet Oncology (2017)
Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes
Authors: Lyla Saeed, Mrinal M Patnaik, Kebede H. Begna, Aref Al-Kali, Mark R Litzow, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood (2016)
Skin cancer surveillance and malignancies in patients with chronic lymphocytic leukemia (CLL).
Authors: Aaron Scott Mansfield, Kari G. Rabe, Susan M. Schwager, Timothy Call, Jerry D. Brewer, Tait D. Shanafelt
Journal: Journal of Clinical Oncology (2012)

184 Background: Patients with CLL are at higher risk of developing melanoma and other skin malignancies. The survival of patients with melanoma is worse, stage for stage, in patients with CLL than patients without. It is thought that early diagnosis of skin cancer is critical to improving survival in CLL patients. To promote early diagnosis and education on skin cancer prevention, the Mayo Clinic CLL group has recommended that CLL patients be referred for full body skin evaluation within 6 months of diagnosis. We sought to determine adherence to these guidelines by our group and identify prevalence of skin malignancies within 6 months of diagnosis. Methods: We identified patients who lived within 30 miles of Mayo Clinic who were diagnosed with CLL between 01/01/2004 and 01/01/2012 using the Mayo Clinic CLL database. Charts were reviewed for skin examinations, referrals to dermatology/primary care within 6 months of diagnosis of CLL, and diagnosis of a skin malignancy. Results: There were 107 patients newly diagnosed with CLL included in this study. Of the 79 patients who received their primary care at Mayo Clinic, 40 (51%) had a documented whole body skin exam by either a dermatologist or primary care provider within six months of diagnosis. Nine of these 40 patients (23% of examined patients; 8% overall cohort) had a skin malignancy: 2 patients had basal cell carcinomas, 6 patients had squamous cell carcinomas, and 1 patient had malignant melanoma. Prophylactic skin care recommendations could be documented for only 28 (26%) of patients. Conclusions: At least 8% of patients in this locally dwelling cohort with newly diagnosed CLL had a skin malignancy identified within six months of diagnosis (number needed to screen for 1 skin cancer: 13). Of patients referred to dermatology 23% had a skin malignancy (number needed to screen: 4.3). Referrals for screening skin examinations at diagnosis in patients with CLL could have an immediate impact for this at-risk population.
446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers
Authors: K.H. Lee, J.-C. Soria, E. Felip, M. Cobo, S. Lu, K. Syrigos, E. Goker, V. Georgoulias, W. Li, S. Guclu, D. Isla, A. Ardizzoni, S.M. Gadgeel, N. Dupuis, N.J. Gibson, N. Kämer, C. Bühnemann, F. Solca, E. Ehrnrooth, G. Goss
Journal: Annals of Oncology (2016)
Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20%
Authors: Kenneth Paris, Elie Haddad, Iftikhar Hussain, Nicholas Brodszki, Amy Liebl Darter, Werner Engl, Barbara McCoy, Leman Yel
Journal: Journal of Allergy and Clinical Immunology (2017)
Concomitant Atrial Fibrillation Surgery for People Undergoing Cardiac Surgery
Authors: Mark D. Huffman, S. Chris Malaisrie, Kunal N. Karmali
Journal: JAMA Cardiology (2017)

Should patients with preoperative atrial fibrillation who are undergoing cardiac surgery undergo concomitant atrial fibrillation surgery?There is moderate-quality evidence that concomitant atrial fibrillation surgery approximately doubles the likelihood of freedom from atrial fibrillation, atrial flutter, or atrial tachycardia while not receiving antiarrhythmic medications at least 3 months after the procedure with a small absolute increase in needing a permanent pacemaker.
BMET-34. POSTOPERATIVE RADIOSURGERY FOR THE TREATMENT OF BRAIN METASTASES: EVALUATION OF LOCAL RECURRENCE AND LEPTOMENINGEAL DISEASE
Authors: Paul Foreman, Bradford Jackson
Journal: Neuro-Oncology (2016)

In patients undergoing surgical resection of a metastatic brain tumor, whole brain RT may be added to reduce the risk of recurrence and neurologic death. Focal radiation has the potential to mitigate neurocognitive side effects. We present an institutional experience of postoperative radiosurgery for the treatment of brain metastases. A retrospective review of a prospectively maintained institutional radiosurgery database was performed for the years 2005-2015 identifying all adult patients treated with postoperative radiosurgery to the tumor bed. Primary endpoints include local recurrence and postoperative LMD. Radiosurgery included single fraction GKS and VMAT, as well as 5-fraction VMAT. The radiosurgery target was limited to the postoperative cavity. Focal dural enhancement more than 5mm away from the cavity was included as LMD failure. Ninety-one patients received adjuvant focal radiation for a brain metastasis. Median radiographic follow-up among patients who had not developed a local failure was 9 months. The most common histology was non-small cell lung cancer (43%) followed by melanoma (19%) and breast (12%). Of the 91 patients, 20 (22%) developed local recurrence and 32 (35%) experienced postoperative LMD. Freedom from local recurrence and LMD at 1 year was 84% and 69%, respectively. In multi-variate models, predictors of local failure included the presence of more than one brain metastasis (HR=2.65, p = 0.036) and a preoperative tumor diameter of >3 cm (HR=4.16, p = 0.057). There was a trend to a higher risk of LMD with > 1 tumor (HR 2.07, p = 0.057) and breast cancer (HR 2.37, p=0.072). More than one metastasis is an independent predictor of local and leptomeningeal failure following postoperative radiosurgery. The high rate of LMD was likely related to the liberal definition of LMD to include focal dural recurrences. The clinical significance of limited dural dissemination requires additional study.
Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.
Authors: Rakhee Vaidya, Naseema Gangat, Sergio Siragusa, Susan Schwager, Curtis A. Hanson, Michelle Elliott, Animesh D. Pardanani, Ayalew Tefferi
Journal: Blood (2009)
AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer
Authors: M. Del Re, E. Biasco, S. Crucitta, L. Derosa, E. Rofi, A. Farnesi, A. Sbrana, G. Restante, L. Galli, A. Falcone, G. Jenster, R.H.N. van Schaik, R. Danesi
Journal: Annals of Oncology (2016)
A novel monoclonal antibody against the von Willebrand Factor A2 domain reduces its cleavage by ADAMTS13
Authors: Lulu Zhang, Jian Su, Fei Shen, Zhenni Ma, Yiming Zhao, Lijun Xia, Changgeng Ruan
Journal: Journal of Hematology & Oncology (2017)

We developed a novel murine monoclonal antibody (mAb) against the C-terminal α-helix of the human von Willebrand factor A2, designated SZ-179. We showed that SZ-179 inhibited the interactions between VWF and ADAMTS13 and prevented the degradation of high molecular weight VWF multimers. Importantly, SZ-179 reduced the proteolysis of VWF-R1597W mutant by rADAMTS13 dose-dependently under native conditions. Our findings reveal a potential therapeutic target for bleeding disorders.
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
Authors: M. Suenaga, M. Schirripa, S. Cao, W. Zhang, D. Yang, S. Murgioni, D. Rossini, F. Marmorino, A. Mennitto, Y. Ning, S. Okazaki, M.D. Berger, Y. Miyamoto, R. Gopez, A. Barzi, T. Yamaguchi, F. Loupakis, H.-J. Lenz
Journal: Annals of Oncology (2017)
Dexpramipexole effectively lowers blood and tissue eosinophils in subjects with chronic rhinosinusitis with nasal polyps
Authors: Calman Prussin, Tanya M. Laidlaw, Reynold A. Panettieri, Berrylin J. Ferguson, Nithin D. Adappa, Andrew P. Lane, Stella Lee, Mary Sullivan, Don Archibald, Steven I. Dworetzky, Greg Hebrank, Michael E. Bozik
Journal: Journal of Allergy and Clinical Immunology (2017)
ACQUIRED DIGITAL FIBROKERATOMAS*
Authors: VERMEN V. M. VERALLO
Journal: British Journal of Dermatology (1968)

SUMMARY.— Thirty‐two cases are reported of the tumour recently described as acquired digital fibrokeratoma. The histological features are described in detail and the differentiation from other superficially similar tumours is emphasized. The possible histogenesis is discussed. Since not all such lesions are on the digits the term acquired fibrokeratoma is suggested as appropriate.
Study of Protein Haptenation By Biotinylated Clavulanic Acid: Usefulness in Studies on Allergy Towards Betalactams
Authors: Angela Martin-Serrano, Nekane Barbero, Adriana Ariza, Tahia D. Fernandez, Ezequiel Perez-Inestrosa, Maria Salas, Cristobalina Mayorga, Dolores Perez-Sala, Maria J. Torres, Maria I. Montañez
Journal: Journal of Allergy and Clinical Immunology (2017)
Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.
Authors: David Margel, Stanley Yap, Nathan Lawrentschuk, Laurence Klotz, Masoom A. Haider, Antonio Finelli, Alexandre Zlotta, John Trachtenberg, Neil Eric Fleshner
Journal: Journal of Clinical Oncology (2012)

30 Background: One troubling aspect of active surveillance (AS) is that a subset of patients diagnosed as very-low risk prostate cancer (PCa) appear to be under sampled and, in fact, harbour larger often higher grade cancers.The aim of this study is to report MRI findings among unselected men with low-risk PCa prior to AS. Methods: We prospectively enrolled men with low-grade, low-risk, localized PCa. All patients underwent multiparametric endorectal coil MRI scanning and offered a confirmatory biopsy within one year of MRI. The primary outcome was the impact of MRI in identifying patients reclassified as no longer fulfilling AS criteria by a confirmatory biopsy. We further aimed to identify clinical parameters associated with reclassification. Cohort was stratified as follows: normal MRI; cancer on MRI concordant with initial biopsy (less than 1 cm); cancer on MRI larger than 1cm. We performed a univariate analysis to assess differences in clinical parameters between groups. Results: MRI did not detect cancer in 23 (38%) while MRI and initial biopsy were concordant in 24 patients (40%). MRI detected a 1cm or larger lesion in 13 patients (22%). Eighteen patients (32.14%) reclassified. When no cancerous lesion was identified on MRI only 2 patients (3.5%) reclassified. The positive and negative predictive values for MRI predicating reclassification were 83% (95% CI, 73%-93%) and 81% (95% CI, 71%-91%), respectively. PSA density was elevated among patients with larger than 1 cm MRI lesions compared to those with no cancer on MRI (medians of 0.15 vs 0.07 ng/ml/cc, respectively p=0.016). Conclusions: MRI appears to have a high yield in predicting reclassification among men choosing AS. Upon confirmation of our results MRI may be used to better select and guide patients before AS.
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMATOID GRANULOMATOSIS: A SURVEY OF THE LYMPHOMA WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT)
Authors: K. Siegloch, N. Schmitz, B. Friedrichs, E. Hamilton, G. W. Van Imhoff, S. Montoto, J. J. Luan, J. M. Ribera, R. Delage, U. Duehrsen, P. Dreger, A. Sureda
Journal: Annals of Oncology (2011)
A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Prognostic Score (MPS).
Authors: Andrew Chung Yang, Alison Wiesenthal, Andrew S. Epstein, Junting Zheng, Jessica Goldberg, Jason Meadows, Eileen Mary O'Reilly, Paul A. Glare
Journal: Journal of Clinical Oncology (2016)

36 Background: A major limitation of prognostic tools such as the Eastern Cooperative Oncology Group (ECOG), Karnofsky, and Palliative Performance Scale is a reliance on subjective clinical assessment. An objective tool, the Glasgow Prognostic Score (GPS) is derived from C-reactive Protein (CRP) and albumin and has been validated in patients with operable and inoperable malignancies. One disadvantage of this tool is that CRP is not routinely measured in the United States. We examined if the Neutrophil-Lymphocyte Ratios (NLR) (Ahn, H.K., et al., Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients. J Palliat Med, 2016) could be substituted for CRP in the GPS to predict survival in patients with advanced pancreatic adenocarcinoma. Methods: A retrospective chart review identified patients at MSKCC with pathology-confirmed stage IV pancreatic adenocarcinoma diagnosed between 2011 to 2014. Pre-treatment absolute neutrophil count, absolute lymphocyte count, and albumin were extracted. The NLR for each patient was calculated and assigned: NLR ≤ 4 g/dl = 0, NLR &gt; 4 g/dl = 1; serum albumin &gt; 4 g/dl = 0, and serum albumin &lt; 4 g/dl = 1. Combining NLR and albumin scores resulted in a composite MPS score of 0-2, similar to GPS. We evaluated the association of the MPS with overall survival. Results: N = 833 patients were identified with median survivals summarized in the table below. A log-rank test showed statistically significant differences in survival between MPS groups (p&lt;0.00005). The MPS on univariate analysis had a HR of 1.36 (95% CI 1.23 – 1.50, p&lt;0.0005) associated with overall survival. Conclusions: The MPS, a novel composite of NLR and albumin, is an objective prognostic tool that divided this sample of patients into three clinically distinct subgroups. Further interrogation will control for performance status, disease characteristics and anti-cancer therapy. [Table: see text]